Description: <b>Brucea javanica</b> is a plant in the family Simaroubaceae.<br>
<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8971814/">
"Brucea javanica (Ya-dan-zi in Chinese)</a> is a well-known Chinese herbal medicine, which is traditionally used in Chinese medicine for the treatment of intestinal inflammation, diarrhea, malaria, and cancer. The formulation of the oil (Brucea javanica oil) has been widely used to treat various types of cancer." <br>
Pathways:<br>
-Induce mitochondrial dysfunction leading to cytochrome c release and subsequent activation of caspases.<br>
-Inhibit Akt phosphorylation/activity<br>
-Inhibit NF-κB activation<br>
-Inhibition of STAT3 phosphorylation <br>
-Cell cycle at specific checkpoints (e.g., G0/G1 or G2/M)<br>
-Elevating intracellular ROS<br>
<br>
well-known metabolites such as Brusatol and Bruceine D. <br>
vital metabolite found in BJ is terpenoids. <br>
-oleic acid and linoleic acid were found to be the active components of BJO.<br>
-BJOEI consists of 85% triglycerides and 10% oleic acids, interlaced with saturated and unsaturated fatty acids along with triterpene alcohols. <br>
<p><b>Brucea javanica</b> — Brucea javanica (L.) Merr., commonly abbreviated BJ and also known in Chinese medicine as Yadanzi, is the medicinal fruit/seed source of a Simaroubaceae shrub and a botanical anticancer agent whose clinically deployed form is most often Brucea javanica oil emulsion injection (BJOEI/BJOEI). It is best classified as a multi-component botanical drug platform rather than a single-molecule drug, because whole-fruit extracts, seed oil emulsions, and isolated quassinoids such as bruceine D and brusatol have overlapping but non-identical mechanisms. The major mechanistic payload appears to divide between quassinoids, which are the principal high-potency antitumor metabolites, and the fatty-oil fraction, whose main constituent is oleic acid and which underlies the marketed emulsion products. Clinically, BJ is used mainly as an adjunctive anticancer therapy in China rather than a globally standardized oncology drug, and interpretation of the literature requires separating crude BJ, BJO/BJOEI, and isolated quassinoids because their PK, toxicity, and exposure constraints differ materially.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Mitochondrial apoptosis induction with cytochrome c release, caspase activation, and BCL-2 family shift.</li>
<li>ROS-dependent stress signaling with MAPK engagement, especially for quassinoids such as bruceine D.</li>
<li>Suppression of pro-survival signaling including PI3K/Akt, NF-κB, and in some models STAT3.</li>
<li>Autophagy modulation, which may be induced or blocked depending on formulation, cell type, and context.</li>
<li>Cell-cycle arrest and anti-proliferative signaling at G0/G1 or G2/M checkpoints.</li>
<li>Anti-migration, anti-invasion, and anti-glycolytic effects in selected solid-tumor models.</li>
<li>Adjunct chemosensitization / radiosensitization and reduction of treatment-related toxicity in some clinical-use settings.</li>
<li>Clinical translation constraint: multi-component composition, formulation-dependent exposure, and uncertain equivalence between in-vitro quassinoid studies and marketed oil-emulsion products.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Native BJ constituents have important delivery limitations. Quassinoids generally have poor aqueous solubility and limited oral bioavailability, while the clinically used oil-emulsion products are formulation-driven and are not pharmacokinetically equivalent to isolated monomers. Oral nanoemulsion/liposomal systems improve exposure in preclinical models, and standard emulsion products are used mainly to bypass solubility constraints rather than to establish predictable monomer-level systemic exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Translation is form-dependent. Many mechanistic papers use purified quassinoids at low-micromolar concentrations, but the marketed clinical product is typically a fatty-oil emulsion dominated by oleic-acid-rich seed oil rather than purified bruceine D or brusatol. Therefore, direct mapping from monomer in-vitro potency to systemic clinical exposure is limited, and mechanism claims should be weighted higher when shown with BJO/BJOEI itself or validated in vivo.</p>
<p><b>Clinical evidence status:</b> Small-to-moderate human evidence exists mainly for adjunctive use in China, especially with chemotherapy, radiotherapy, or local perfusion approaches. Meta-analytic signals suggest improved response and reduced some adverse events in gastric and other digestive-system cancers, but evidence quality is generally limited by study quality and regional concentration. Current status is best categorized as adjunct clinical use with RCT/meta-analysis support of low-to-moderate certainty, not as globally validated monotherapy.</p>
<h3>Mechanistic profile</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Mitochondrial apoptosis program</td>
<td>↑ cytochrome c release; ↑ caspase-9/3; ↓ BCL-2; ↑ apoptosis</td>
<td>↔ / less affected in some models</td>
<td>R-G</td>
<td>Direct tumor-cell killing</td>
<td>Best-supported shared axis across seed oil, oil emulsion, and several quassinoid studies.</td>
</tr>
<tr>
<td>2</td>
<td>Death receptor apoptosis</td>
<td>↑ caspase-8; ↑ extrinsic apoptotic signaling</td>
<td>↔</td>
<td>R-G</td>
<td>Amplifies apoptosis</td>
<td>Strongly supported for seed oil preparations in leukemia models.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial ROS increase</td>
<td>↑ ROS</td>
<td>↔ / uncertain</td>
<td>P-R</td>
<td>Stress-triggered apoptosis and autophagy</td>
<td>Particularly prominent for bruceine D; NAC reversibility supports mechanistic relevance.</td>
</tr>
<tr>
<td>4</td>
<td>MAPK stress signaling</td>
<td>↑ p38/JNK/ERK (context-dependent)</td>
<td>↔</td>
<td>P-R</td>
<td>ROS-linked death signaling</td>
<td>Often downstream of oxidative stress rather than a primary initiating lesion.</td>
</tr>
<tr>
<td>5</td>
<td>PI3K/Akt survival axis</td>
<td>↓ PI3K/Akt signaling</td>
<td>↔</td>
<td>R-G</td>
<td>Suppresses growth and survival</td>
<td>Seen across BJ/BJO literature and in quassinoid-focused studies; central but formulation-dependent.</td>
</tr>
<tr>
<td>6</td>
<td>NF-κB inflammatory survival axis</td>
<td>↓ NF-κB activation</td>
<td>↔ / uncertain</td>
<td>R-G</td>
<td>Reduces anti-apoptotic resistance</td>
<td>Likely contributes to chemosensitization and apoptosis facilitation in some tumors.</td>
</tr>
<tr>
<td>7</td>
<td>Autophagy control</td>
<td>↑ or ↓ autophagy (context-dependent)</td>
<td>↔</td>
<td>R-G</td>
<td>Can promote tumor death or alter stress adaptation</td>
<td>Not unidirectional across the literature; should be treated as secondary and model-specific.</td>
</tr>
<tr>
<td>8</td>
<td>Cell-cycle checkpoint control</td>
<td>↑ G0/G1 or G2/M arrest</td>
<td>↔</td>
<td>G</td>
<td>Anti-proliferative restraint</td>
<td>Common downstream phenotype, but not the most central mechanistic driver.</td>
</tr>
<tr>
<td>9</td>
<td>NRF2 / HO-1 redox survival axis</td>
<td>↓ NRF2 signaling (context-dependent)</td>
<td>↔ / possible stress sensitization</td>
<td>R-G</td>
<td>Redox-defense suppression and chemosensitization</td>
<td>Most relevant for isolated brusatol from Brucea javanica; less established as a dominant mechanism for BJO/BJOEI as a whole. Specificity is debated because brusatol may act beyond NRF2 alone.</td>
</tr>
<tr>
<td>10</td>
<td>STAT3 axis</td>
<td>↓ STAT3 phosphorylation (model-dependent)</td>
<td>↔</td>
<td>R-G</td>
<td>Limits proliferation and inflammatory signaling</td>
<td>Supported in parts of the BJ literature, but less universally than apoptosis/ROS/Akt axes.</td>
</tr>
<tr>
<td>11</td>
<td>Glycolysis and metastatic metabolism</td>
<td>↓ aerobic glycolysis; ↓ invasion/migration</td>
<td>↔</td>
<td>G</td>
<td>Anti-metastatic metabolic suppression</td>
<td>Recent oral squamous carcinoma work links BJO to MTFR2-related glycolytic suppression and SOD2/H2O2 modulation.</td>
</tr>
<tr>
<td>12</td>
<td>Radiosensitization or Chemosensitization</td>
<td>↑ sensitivity to chemo/radiotherapy</td>
<td>Possible ↓ treatment toxicity</td>
<td>G</td>
<td>Adjunct therapeutic leverage</td>
<td>More clinically relevant for BJOEI than for isolated monomers; supported mainly by adjunct-use studies and meta-analyses.</td>
</tr>
<tr>
<td>13</td>
<td>Clinical Translation Constraint</td>
<td>Formulation heterogeneity; exposure uncertainty; monomer vs emulsion mismatch</td>
<td>ADR risk from product and excipients</td>
<td>G</td>
<td>Limits generalization</td>
<td>Whole BJ, BJO/BJOEI, and isolated quassinoids should not be treated as pharmacologically interchangeable.</td>
</tr>
</table>
<p>P: 0–30 min<br>R: 30 min–3 hr<br>G: >3 hr</p>